Indeed, in a study to evaluate histone deacetylase inhibitors (HDACi) as potential anti-CSC therapy, only the BC cells with low XIST expression exhibit HDACi response in mouse xenograft models, and this response is associated with a significant reduction of CSCs [32]. The gene discussed is XIST; the disease is breast cancer.